Search
Statistics
We have 222 registered usersThe newest registered user is raheelmemon
Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
Switching to Aripiprazole May Reduce Metabolic Risk in patients with Schizophrenia
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psycho-Pharmacology
Page 1 of 1
Switching to Aripiprazole May Reduce Metabolic Risk in patients with Schizophrenia
Admin Thu Jun 02, 2011 1:59 pm
May 25, 2011 (Honolulu, Hawaii) — Switching from the atypical antipsychotics olanzapine, quetiapine, or risperidone to the atypical antipsychotic aripiprazole may reduce metabolic risk in patients with schizophrenia, new research suggests.
Scott Stroup, MD, MPH, director of the Program for Intervention Effectiveness Research at Columbia University Medical Center in New York City
"The commonly used antipsychotic medications are associated with metabolic problems that are risk factors for cardiovascular disease [CVD]. And we know that people with schizophrenia are dying prematurely from CVD. So we wanted to try and find solutions to that problem," Dr. Stroup said.
Details here ---> http://www.medscape.com/viewarticle/743435?src=smo_pysch
Scott Stroup, MD, MPH, director of the Program for Intervention Effectiveness Research at Columbia University Medical Center in New York City
"The commonly used antipsychotic medications are associated with metabolic problems that are risk factors for cardiovascular disease [CVD]. And we know that people with schizophrenia are dying prematurely from CVD. So we wanted to try and find solutions to that problem," Dr. Stroup said.
Details here ---> http://www.medscape.com/viewarticle/743435?src=smo_pysch
Admin- Admin
- Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia -
Similar topics» Antidepressants and risk of DM/Metabolic Abnormalities
» What is the rate of metabolic syndrome in schizophrenia?
» Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with Clozapine.
» Antipsychotics & Risk of Mortality in Patients with Dementia
» Normalization of Risperidone-Induced Hyperprolactinemia with the Addition of Aripiprazole
» What is the rate of metabolic syndrome in schizophrenia?
» Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with Clozapine.
» Antipsychotics & Risk of Mortality in Patients with Dementia
» Normalization of Risperidone-Induced Hyperprolactinemia with the Addition of Aripiprazole
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psycho-Pharmacology
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
» L-Methylfolate: Who Will benefit
» Vitamins & Supplements in Clinical Practice.
» Imaging Biomarkers for Outcomes in Mild TBI
» Q.5 Clozapine Neutopenia
» Treating Disorders!
» Cortical Abnormalities in Adults & Adolescents with MDD
» Efficacy of Antipsychotics in Pediatric Acute Mania
» Obsessive Compulsive Disorder in Adults: Which Treatment is Better?